Tech Company Financing Transactions
Immunicom Funding Round
Immunicom closed a $11 million Series B financing round on 7/3/2019. Backers included private investors.
Transaction Overview
Company Name
Announced On
7/3/2019
Transaction Type
Venture Equity
Amount
$11,000,000
Round
Series B
Investors
Proceeds Purpose
The proceeds from this financing will help fund the 170-patient, randomized, multi-center, triple-negative breast cancer clinical trial the company began May 31, while also accelerating continued expansion of its global strategic partnerships.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6048 Cornerstone Ct. W D
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Overview
Headquartered in San Diego, California Immunicom's team consists of healthcare industry experts who each have over 25 years of global senior executive experience in private and Fortune 50 medical technology and pharmaceutical companies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Amir Jafri
Chief Financial Officer
David Lopez
Chief Medical Officer
Adam Ostrowski
Chief Scientific Officer
Steven Josephs
Vice President
Johan Louw
VP - Bus. Development
Steve Prince
VP - Operations
Farah Awan
VP - Regulatory Affairs
Marilyn Panahi
Browse more venture capital transactions:
Prev: 7/3/2019: Tara AI venture capital transaction
Next: 7/3/2019: Kyash venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs